DE1670820A1 - Verfahren zur Herstellung von vernetzten Proteinen - Google Patents
Verfahren zur Herstellung von vernetzten ProteinenInfo
- Publication number
- DE1670820A1 DE1670820A1 DE19671670820 DE1670820A DE1670820A1 DE 1670820 A1 DE1670820 A1 DE 1670820A1 DE 19671670820 DE19671670820 DE 19671670820 DE 1670820 A DE1670820 A DE 1670820A DE 1670820 A1 DE1670820 A1 DE 1670820A1
- Authority
- DE
- Germany
- Prior art keywords
- production
- cross
- column
- linked proteins
- fractions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 title claims description 4
- 108090000623 proteins and genes Proteins 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 238000000034 method Methods 0.000 title claims description 3
- 230000000937 inactivator Effects 0.000 claims description 9
- 108060005987 Kallikrein Proteins 0.000 claims description 8
- 102000001399 Kallikrein Human genes 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 150000002463 imidates Chemical class 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229920005654 Sephadex Polymers 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- -1 ester hydrochloride Chemical class 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 description 1
- 101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 description 1
- 229940122920 Kallikrein inhibitor Drugs 0.000 description 1
- 102100025421 Serine protease inhibitor Kazal-type 6 Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- VYTBPJNGNGMRFH-UHFFFAOYSA-N acetic acid;azane Chemical compound N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O VYTBPJNGNGMRFH-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Refrigerator Housings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEF0051832 | 1967-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1670820A1 true DE1670820A1 (de) | 1971-04-01 |
Family
ID=7104937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19671670820 Pending DE1670820A1 (de) | 1967-03-16 | 1967-03-16 | Verfahren zur Herstellung von vernetzten Proteinen |
Country Status (13)
| Country | Link |
|---|---|
| AT (1) | AT283588B (cs) |
| BE (1) | BE712280A (cs) |
| CH (1) | CH486493A (cs) |
| DE (1) | DE1670820A1 (cs) |
| DK (1) | DK119270B (cs) |
| ES (1) | ES351635A1 (cs) |
| FI (1) | FI46970C (cs) |
| FR (1) | FR1565575A (cs) |
| GB (1) | GB1173861A (cs) |
| IL (1) | IL29465A (cs) |
| NL (1) | NL6803643A (cs) |
| NO (1) | NO120839B (cs) |
| SE (1) | SE342241B (cs) |
-
1967
- 1967-03-16 DE DE19671670820 patent/DE1670820A1/de active Pending
-
1968
- 1968-02-12 CH CH203368A patent/CH486493A/de not_active IP Right Cessation
- 1968-02-13 IL IL2946568A patent/IL29465A/en unknown
- 1968-02-28 FI FI53368A patent/FI46970C/fi active
- 1968-03-04 AT AT207468A patent/AT283588B/de active
- 1968-03-12 NO NO95368A patent/NO120839B/no unknown
- 1968-03-14 NL NL6803643A patent/NL6803643A/xx unknown
- 1968-03-14 GB GB1245968A patent/GB1173861A/en not_active Expired
- 1968-03-14 DK DK109168A patent/DK119270B/da unknown
- 1968-03-15 BE BE712280D patent/BE712280A/xx unknown
- 1968-03-15 ES ES351635A patent/ES351635A1/es not_active Expired
- 1968-03-15 SE SE344868A patent/SE342241B/xx unknown
- 1968-03-15 FR FR1565575D patent/FR1565575A/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB1173861A (en) | 1969-12-10 |
| IL29465A (en) | 1971-12-29 |
| DK119270B (da) | 1970-12-07 |
| NL6803643A (cs) | 1968-09-17 |
| NO120839B (cs) | 1970-12-14 |
| FI46970B (cs) | 1973-05-02 |
| FR1565575A (cs) | 1969-05-02 |
| BE712280A (cs) | 1968-09-16 |
| CH486493A (de) | 1970-02-28 |
| ES351635A1 (es) | 1969-06-16 |
| AT283588B (de) | 1970-08-10 |
| SE342241B (cs) | 1972-01-31 |
| FI46970C (fi) | 1973-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH646061A5 (de) | Blutgerinnungsfoerdernde praeparation auf basis von humanproteinen sowie verfahren zu ihrer herstellung. | |
| DE69016383T2 (de) | Supersulfatierte Heparine. | |
| DE2201993A1 (de) | Enzympraeparat und Verfahren zu dessen Herstellung | |
| DE2924744C2 (de) | Gewinnung von reiner Urokinase | |
| DE2551966C3 (de) | Verfahren zum Reinigen von Urokinase | |
| DE1670820A1 (de) | Verfahren zur Herstellung von vernetzten Proteinen | |
| EP0065286A2 (de) | Verfahren zum Reinigen bzw. Anreichern von biologisch aktiven Proteinen und hierzu geeignetes Mittel | |
| DE3586952T2 (de) | Fibrinophiler urokinase-komplex und dessen herstellung. | |
| DE2001902A1 (de) | Verfahren zur Anreicherung von Proteinen | |
| Emiliani et al. | Induced autolysis of Aspergillus oryzae (A. niger group) IV. Carbohydrates | |
| DE2428955A1 (de) | Verfahren zur extraktion von bestandteilen mit in vivo antikoagulierender wirkung aus schlangengiften und daraus erhaltene produkte | |
| DE1642612A1 (de) | Die Verwendung von Erythrozyten zur Gewinnung bzw.Isolierung eines Plasminogen-Aktivators | |
| EP0180859B1 (de) | Verfahren zur Reinigung sowie Pasteurisierung von Urokinase | |
| DE3850407T2 (de) | Protein mit inhibierender wirkung auf die entzündungserregende phospholipase a2. | |
| WO1991004275A1 (de) | Neue proteine geeignet zur bekämpfung von krankheiten sowie zum schutz von weidevieh gegen zecken | |
| DE4318235B4 (de) | Verfahren zur Herstellung von hochreinen Deferoxamin-Salzen | |
| AT336182B (de) | Verfahren zur herstellung eines prothrombinkomplexes | |
| DE926085C (de) | Verfahren zur Herstellung von Hemmstoffen des Blutgerinnungssystems | |
| DE2350691C2 (de) | Herstellung von Pankreas-Elastase | |
| DE2116377C3 (de) | Verfahren zur Gewinnung des Kallikrein-Trypsin-Inhibitors aus Rinderorganen | |
| DE560463C (de) | Verfahren zur Trennung von Proteinasen und Carboxy-Polypeptidasen des Pankreas | |
| DE1768362A1 (de) | Dextranderivat und Verfahren zu seiner Herstellung | |
| DE1617661A1 (de) | Verfahren zur Herstellung hochreiner Gonadotropine auf chromatographischem Wege | |
| DE1235842B (de) | Verfahren zur Gewinnung immunologisch einheitlicher Streptokinase unter sterilen Bedingungen | |
| DE2151265C3 (de) | Biotechnisches Verfahren zur Herstellung von a-Amylase |